Recce Pharmaceuticals Ltd RECEF
Trading Information
- Previous Close Price
- $0.50
- Day Range
- $0.22–0.22
- 52-Week Range
- $0.22–0.60
- Bid/Ask
- $0.38 / $0.60
- Shares Outstanding
- 305.77M
- Market Cap
- $63.62M
- Volume/Avg
- 183,507 / 144,882
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Recce Pharmaceuticals Ltd is an Australia-based, globally-focused biotechnology company that is pioneering the development and commercialisation of a drug discovery and development business commercialising new Classes of synthetic anti-infectives with broad-spectrum activity designed to address the urgent health threat of antibiotic-resistant superbugs and emerging viral pathogens. Its patented candidate, RECCE 327, has been developed for the treatment of life-threatening bacterial infections. It has one segment, which is the research and development of pharmaceutical drugs. Geographic segments are Australia, the UK, and the USA, of which the majority of the revenue comes from Australia. It offers antibiotic drugs to treat bacterial infections for Sepsis, Escherichia coli, and Others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- —
- Website
- https://www.recce.com.au
Valuation
|
Metric
|
RECEF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RECEF
|
|---|---|
Quick Ratio | 0.40 |
Current Ratio | 0.44 |
Interest Coverage | −8.09 |
Quick Ratio
RECEF
Profitability
|
Metric
|
RECEF
|
|---|---|
Return on Assets (Normalized) | −181.37% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
RECEF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<!!?!BJ | LOCK|%C$p | $136B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|wF^%FKz | LOCK|WH$## | $84B | |||
| Moderna Inc
MRNA
| LOCK|bQT>b&l | LOCK|w& | $81B | |||
| argenx SE ADR
ARGX
| LOCK|c>!ZHV | LOCK|j^ | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|gg#>#? | LOCK|X^H | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|#%&Q#$p | LOCK|$LkhP | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|H<GK#Fg | LOCK|ch?!P | $28B | |||
| Incyte Corp
INCY
| LOCK|W&n?K! | LOCK|R< | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|sT><<# | LOCK|?h& | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|>r@%<&T | LOCK|>t> | $14B |
United States